GLP-1 agonists are a class of injectable medications that are used for type 2 diabetes and weight management
GLP-1 RAs activate GLP-1 receptors in the nucleus accumbens and the ventral tegmental area, which represent a key reward pathway, as well as modulate energy intake and expenditure by activating anorexigenic proopiomelanocortin (POMC)/cocaine and amphetamine regulated transcript (CART) neurons and inhibiting orexigenic neuropeptide Y (NPY)/agouti-related peptide (AgRP) neurons in the arcuate nucleus (2427)
Think of them as gentle helpers that nudge your bodys natural systems to do what they already know how to do, just a little more effectively
The role of -cell GLP-1 signaling in glucose regulation and response to diabetes drugs
22 Variations in formulation, dosing schedules, and dual agonism with tirzepatide influence tolerability, emphasizing the need for individualized therapy
In addition, aptf-2 RNAi lowered PZ germ cell number, as did an aptf-2(qm27) mutant that harbors a point mutation in the APTF-2 DNA binding domain (Figs
